{"id":3803,"date":"2025-01-12T03:25:12","date_gmt":"2025-01-12T03:25:12","guid":{"rendered":"https:\/\/kodiak-sciences-develop.go-vip.net\/dotcom\/?page_id=3803"},"modified":"2026-11-03T14:00:37","modified_gmt":"2026-11-03T14:00:37","slug":"our-pipeline","status":"publish","type":"page","link":"https:\/\/kodiak-sciences-develop.go-vip.net\/dotcom\/our-pipeline\/","title":{"rendered":"Our Pipeline"},"content":{"rendered":"\n
\"\"<\/span>
\n

GENERATION 2.0<\/h2>\n\n\n\n

Inspired to build the world’s leading high-science retina pipeline<\/p>\n<\/div><\/div>\n\n\n\n\n

OUR PIPELINE<\/h2>\n\n\n\n
\n\n\n\n

Our pipeline is designed to address key limitations of today\u2019s therapies across a broad spectrum of retinal diseases.<\/p>\n\n\n\n

\n
\n
\n
Zenkuda<\/div>\n \n
\n \n
\n
Pre-clinical<\/div>\n
Pre-IND<\/div>\n
Phase 1\/2<\/div>\n
Phase 3<\/div>\n <\/div>\n \n
\n \n
BLA<\/div>\n
Commercial<\/div>\n <\/div>\n <\/div>\n

BLA-ready profile in wet AMD, DR and RVO<\/p><\/div>\n <\/div>\n

\n
Retinal vascular diseases<\/div>\n
Diabetic retinopathy<\/div>\n
Wet age-related macular degeneration<\/div>\n
Retinal vein occlusion<\/div>\n <\/div>\n<\/div>\n
\n
\n
Tabirafusp-ted (KSI-501)<\/div>\n \n
\n \n
\n
Pre-clinical<\/div>\n
Pre-IND<\/div>\n
Phase 1\/2<\/div>\n
Phase 3<\/div>\n <\/div>\n \n
\n
BLA<\/div>\n
Commercial<\/div>\n <\/div>\n <\/div>\n

DAYBREAK (wet AMD): Primary endpoint met<\/p>

ALTO (DME): Actively recruiting<\/p><\/div>\n <\/div>\n

\n
Retinal vascular diseases<\/div>\n
Wet age-related macular degeneration<\/div>\n
Diabetic macular edema<\/div>\n <\/div>\n<\/div>\n
\n
\n
KSI-101<\/div>\n \n
\n \n
\n
Pre-clinical<\/div>\n
Pre-IND<\/div>\n
Phase 1\/2<\/div>\n
Phase 3<\/div>\n <\/div>\n \n
\n
BLA<\/div>\n
Commercial<\/div>\n <\/div>\n <\/div>\n

PEAK and PINNACLE (MESI) actively recruiting<\/p><\/div>\n <\/div>\n

\n
Macular edema secondary to inflammation<\/div>\n <\/div>\n<\/div>\n<\/div>\n\n\n\n\n\n\n\n\n

The product candidates described on this page are investigational and have not been approved for use by the U.S. Food and Drug Administration (FDA) or other regulatory authorities. Their safety and effectiveness for the uses described have not been established by those authorities.<\/p>\n\n\n\n\n

OUR CANDIDATES<\/h2>\n\n\n\n
\n\n\n\n

\n
\n
\n
\n \n <\/div>\n
\n

Zenkuda\u2122 (tarcocimab)<\/span>
\n Anti-VEGF\n <\/p>\n <\/div>\n <\/div>\n

\n
\n \n <\/div>\n
\n

Tabirafusp-ted (KSI-501)<\/span>
\n Anti-IL-6, VEGF trap\n <\/p>\n <\/div>\n <\/div>\n

\n
\n \n <\/div>\n
\n

KSI-101<\/span>
\n Anti-IL-6, VEGF trap\n <\/p>\n <\/div>\n <\/div>\n

\n
\n \n <\/div>\n
\n

Multi-mechanistic medicines<\/span>
1 Molecule, Many targets<\/span><\/p>\n <\/div>\n <\/div>\n <\/div>\n

\n
<\/div>\n
<\/div>\n
<\/div>\n
<\/div>\n <\/div>\n<\/div><\/p>\n\n\n

\n
\n
\n
\n
\n \n \n Zenkuda\u2122 (tarcocimab)<\/strong>
\n Anti-VEGF\n <\/span>\n <\/div>\n
\n

One investigational anti-VEGF biologic designed to deliver immediate and durable disease control<\/h2>\n
\n

Zenkuda (tarcocimab tedromer) is our most advanced program, supported by five successful Phase 3 studies in wet age-related macular degeneration, diabetic retinopathy and retinal vein occlusion.

Across the clinical program, Zenkuda demonstrated consistent 6-month predominant durability and favorable safety. Designed for flexible dosing from 1 to 6 months, Zenkuda has the potential to be a mainstay biologic for a broad range of patients.<\/p>\n

\n